Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | MK-1248 + Pembrolizumab |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | not applicable |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Advanced Solid Tumor | not applicable | MK-1248 + Pembrolizumab | Phase I | Actionable | In a Phase I trial, MK-1248 in combination with Keytruda (pembrolizumab) demonstrated safety and resulted in an objective response response rate of 18% (3/17, one complete and two partial responses) and a disease control rate of 47% (8/17) in patients with advanced solid tumors (PMID: 32809217; NCT02553499). | 32809217 |
PubMed Id | Reference Title | Details |
---|---|---|
(32809217) | First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. | Full reference... |